ciprofibrate and Metabolic Syndrome studies

ciprofibrate and Metabolic Syndrome

Metabolic Syndrome: A cluster of symptoms that are risk factors for CARDIOVASCULAR DISEASES and TYPE 2 DIABETES MELLITUS. The major components of metabolic syndrome include ABDOMINAL OBESITY; atherogenic DYSLIPIDEMIA; HYPERTENSION; HYPERGLYCEMIA; INSULIN RESISTANCE; a proinflammatory state; and a prothrombotic (THROMBOSIS) state.

Research Excerpts

Excerpt	Relevance	Reference
" In the present study the influence of a four-week daily oral administration of 2 mg/kg body weight ciprofibrate (CAS 52214-84-3) or of 100 mg/kg body weight clofibric acid (CAS 882-09-7) was compared to that of the respective doses of their newly synthesized glycine conjugates in adult male lean and obese Zucker rats."	3.74	Ciprofibrate, clofibric acid and respective glycinate derivatives. Effects of a four-week treatment on male lean and obese Zucker rats. ( Deufel, T; Fleck, C; Karge, E; Lupp, A; Oelschlägers, H, 2008)

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Timeframe

Studies, this research(%)

All Research%

pre-1990

0 (0.00)

18.7374

1990's

0 (0.00)

18.2507

2000's

2 (100.00)

29.6817

2010's

0 (0.00)

24.3611

2020's

0 (0.00)

2.80

Authors

Authors	Studies
Lupp, A	1
Karge, E	1
Deufel, T	1
Oelschlägers, H	1
Fleck, C	1
Paragh, G	1
Seres, I	1
Harangi, M	1
Erdei, A	1
Audikovszky, M	1
Debreczeni, L	1
Kovácsay, A	1
Illyés, L	1
Pados, G	1

Studies

Lupp, A

Karge, E

Deufel, T

Oelschlägers, H

Fleck, C

Paragh, G

Seres, I

Harangi, M

Erdei, A

Audikovszky, M

Debreczeni, L

Kovácsay, A

Illyés, L

Pados, G

Other Studies

2 other studies available for ciprofibrate and Metabolic Syndrome

Article	Year
Ciprofibrate, clofibric acid and respective glycinate derivatives. Effects of a four-week treatment on male lean and obese Zucker rats. Arzneimittel-Forschung, 2008, Volume: 58, Issue:5 Topics: Animals; Body Weight; Chemical and Drug Induced Liver Injury; Clofibric Acid; Cytochrome P-450 Enzym	2008
Ciprofibrate increases paraoxonase activity in patients with metabolic syndrome. British journal of clinical pharmacology, 2006, Volume: 61, Issue:6 Topics: Aryldialkylphosphatase; Case-Control Studies; Cholesterol, LDL; Clofibric Acid; Fibric Acids; Humans	2006

Article

Year

Ciprofibrate, clofibric acid and respective glycinate derivatives. Effects of a four-week treatment on male lean and obese Zucker rats.

Arzneimittel-Forschung, 2008, Volume: 58, Issue:5

Topics: Animals; Body Weight; Chemical and Drug Induced Liver Injury; Clofibric Acid; Cytochrome P-450 Enzym

2008

Ciprofibrate increases paraoxonase activity in patients with metabolic syndrome.

British journal of clinical pharmacology, 2006, Volume: 61, Issue:6

Topics: Aryldialkylphosphatase; Case-Control Studies; Cholesterol, LDL; Clofibric Acid; Fibric Acids; Humans

2006